Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection

Basit Öğe Kaydı
dc.contributor.authorMederacke, I.
dc.contributor.authorYurdaydin, C.
dc.contributor.authorGrosshennig, A.
dc.contributor.authorErhardt, A.
dc.contributor.authorCakaloglu, Y.
dc.contributor.authorYalcin, K.
dc.contributor.authorGurel, S.
dc.date.accessioned2024-04-24T17:11:30Z
dc.date.available2024-04-24T17:11:30Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstract. Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) therapy has previously been associated with impairment of renal function. Limited data are available on the safety of combination therapy with nucleos(t)ide analogues and interferon alfa (IFNa). The aim of this analysis was to assess the renal function during combination therapy with peginterferon alfa-2a (PegIFNa-2a) plus ADV vs either drug alone in patients with hepatitis B/D co-infection. We performed a retrospective analysis of renal function data of patients treated in the Hep-Net/International Delta Hepatitis Intervention Trial 1(HIDIT-1-trial), a European multicenter study to investigate the efficacy of 48 weeks of therapy with PegIFNa-2a+ADV vs either drug alone in 90 patients with chronic hepatitis B/D co-infection. Glomerular filtration rates (GFR) were calculated by CockcroftGault (CG), abbreviated Modification of Diet in Renal Disease (MDRD) study and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. After 48 weeks of therapy GFR values were significantly lower in patients receiving adefovir-containing treatment vs PegIFNa-2a alone [mean difference 16.1 mL/min (CG) and 10.2 mL/min (MDRD), respectively, P < 0.05] while no differences were observed between patients receiving adefovir alone vs combination treatment. Twenty-four weeks after treatment GFR values did not differ between treatment arms. A decrease in GFR =20% was observed more often in patients during adefovir-containing treatment vs PegIFNa-2a alone (P < 0.05) which was confirmed by KaplanMeier analysis. Adefovir-containing but not PegIFNa-2a treatment was associated with a decrease in GFR values in about one-fifth of patients. Combination treatment of PegIFNa-2a+ADV in chronic hepatitis B/D co-infection did not lead to any further impairment of kidney function.en_US
dc.description.sponsorshipHep-Net Study House; German Ministry for Education and Research, BMBF; F. Hoffmann-La Roche; Gilead Sciencesen_US
dc.description.sponsorshipThis study was funded by the Hep-Net Study House (a national network sponsored by the German Ministry for Education and Research, BMBF), F. Hoffmann-La Roche and Gilead Sciences. H Wedemeyer, C Yurdaydin, G. Dalekos, A. Erhardt, S. Zeuzem and MP Manns have received research grants, lecturer fees and travel support from F. Hoffmann-La Roche and Gilead Sciences. I Mederacke has received research grants from F. Hoffmann-La Roche and travel support from Gilead Sciences.en_US
dc.identifier.doi10.1111/j.1365-2893.2011.01560.x
dc.identifier.endpage395en_US
dc.identifier.issn1352-0504
dc.identifier.issn1365-2893
dc.identifier.issue6en_US
dc.identifier.pmid22571900
dc.identifier.scopus2-s2.0-84861101465
dc.identifier.scopusqualityQ2
dc.identifier.startpage387en_US
dc.identifier.urihttps://doi.org/10.1111/j.1365-2893.2011.01560.x
dc.identifier.urihttps://hdl.handle.net/11468/17568
dc.identifier.volume19en_US
dc.identifier.wosWOS:000303858900002
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal of Viral Hepatitis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdefoviren_US
dc.subjectCombination Therapyen_US
dc.subjectGlomerular Filtration Rateen_US
dc.subjectInterferonen_US
dc.subjectRenal Functionen_US
dc.subjectSafetyen_US
dc.titleRenal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infectionen_US
dc.titleRenal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu